Personalis (NASDAQ:PSNL) CFO Sells $449,292.42 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 38,799 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $11.58, for a total transaction of $449,292.42. Following the completion of the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,302,486.14. The trade was a 16.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Price Performance

PSNL stock opened at $11.40 on Monday. The company has a market capitalization of $1.19 billion, a P/E ratio of -11.18 and a beta of 2.27. The company has a 50-day simple moving average of $6.86 and a 200 day simple moving average of $8.10. Personalis, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $11.85.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Equities analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on PSNL. Needham & Company LLC upped their price objective on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Morgan Stanley reduced their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a report on Saturday. Finally, BTIG Research reduced their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Personalis currently has an average rating of “Moderate Buy” and an average price target of $11.00.

Institutional Investors Weigh In On Personalis

Several hedge funds and other institutional investors have recently bought and sold shares of PSNL. Royal Bank of Canada raised its position in Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after acquiring an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its position in Personalis by 75.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after acquiring an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after buying an additional 101,706 shares during the period. Focus Partners Wealth acquired a new stake in Personalis during the 1st quarter worth about $47,000. Finally, JPMorgan Chase & Co. raised its holdings in Personalis by 505.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after buying an additional 24,621 shares during the period. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.